BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 5, 2018
View Archived Issues
Natural and engineered L. lactis as a novel probiotic strategy for cholera protection and diagnosis
Read More
Carbetocin is noninferior to oxytocin to prevent postpartum hemorrhage with better heat stability
Read More
Encochleated atovaquone formulation evaluated in mouse model of pneumocystis pneumonia
Read More
Phase II data presented from ORIENT-1 study of sintilimab in patients with Hodgkin's lymphoma
Read More
Phase I/II data for veliparib as add-on therapy for the treatment of HNSCC
Read More
Clinical trial authorization granted in U.K. for phase I study of FOR-6219
Read More
BMS-986253 well tolerated in phase I study in patients with metastatic or unresectable solid tumors
Read More
RND efflux pump inhibitor MBX-4191 developed at Microbiotix for Gram-negative Enterobacteriaceae
Read More
Conserved haplotype in SGLT1 is linked with lower risk of dietary hyperglycemia
Read More
In vivo evaluation of albumin-binding PSMA analogue [177Lu]HTK-01169 in LNCaP tumor xenograft model
Read More
New Era Pharma presents Sgk1 and/or Sgk2 inhibitors
Read More
Introducing BioWorld Science: supporting R&D decisions through drug discovery and preclinical news
Read More
Celtaxsys divulges new LTA-4 hydrolase inhibitors
Read More
Sanofi and Lead Pharma Holding patent RORC modulators
Read More
Shenzhen Targetrx Biotechnology presents EGFR mutant inhibitors
Read More
Sumitomo Dainippon seeks Japanese approval for thiotepa as pre-HSCT conditioning treatment
Read More
Roche initiates phase I study of RO-7172508 in CEA-positive solid tumors
Read More
TLR7 agonists presented by Apros Therapeutics
Read More
Mitsubishi Tanabe studies MT-7117 in phase II for erythropoietic protoporphyria
Read More
Antibe reports secondary endpoint data from phase IIb GI safety study of ATB-346
Read More
Immutep submits IND to begin phase II study of eftilagimod with Keytruda
Read More
Phase II study of pacritinib in myelofibrosis cleared to continue by IDMC
Read More
IDMC clears phase III study of Tedopi in NSCLC to continue
Read More
